Developer docs
API playgroundTry for free, no card

Search company profiles

ScreenCell

Full company profile

uuid000axj2

Namestring
ScreenCell
Legal namestring
ScreenCell
Websiteurl
screencell.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

ScreenCell is a French biotechnology company founded in 2010 and headquartered in Besançon, France, that develops and commercializes a patented microfiltration technology for isolating circulating tumor cells (CTCs) from whole blood. The company's core technology isolates CTCs based on cell size differential using a membrane filtration approach, eliminating the need for immunological labeling, dedicated instrumentation, or biomarker-based capture. This marker-independent method is positioned to capture a broader spectrum of CTCs, including subpopulations that have undergone epithelial-mesenchymal transition (EMT) and exhibit reduced EpCAM expression, which antibody-based methods miss.

ScreenCell commercializes its technology through a portfolio of seven single-use CTC isolation kits (CYTO, CSB, FCD, FCD-SP, MB, MBSB, LCD) addressing cytology, molecular biology, and cell culture applications. The company sells these consumables directly to academic researchers, clinical laboratories, pharmaceutical and biotech companies, and healthcare providers through a website-based quote system and direct email contact, with no distribution intermediaries. As of January 2026, ScreenCell standardized its kit range to a 2 filtration unit / 1 dilution buffer format with eco-friendly packaging, operationalizing a '1 kit = 1 patient' workflow. The technology is validated across 16 cancer types, supported by 70+ peer-reviewed publications, and has been used in over 30 countries by customers including Mayo Clinic, MSKCC, AP-HP, INSERM, Institut Gustave Roussy, and the University of Manitoba. ScreenCell maintains an 11-50 employee operation and is governed by a leadership team including CEO Nicolas Schlumberger, CSO Georges Uzan, and CTO Sina Naserian.

Short descriptiontext

ScreenCell is a French biotechnology company that commercializes a patented size-based microfiltration technology for isolating circulating tumor cells from whole blood, selling single-use consumable kits directly to academic, clinical, and pharmaceutical research customers across 30+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
circulating tumor cells, CTC isolation kits, liquid biopsy, microfiltration technology, cell isolation devices
Industry2 codes
PRIMARYHLAAABAH
Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAANAC
Companion Diagnostics (CDx) Development & Commercialization
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Liquid Biopsy / CTC Isolation Consumables
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1CTC Isolation Kits
TypeOne Time License
Description

ScreenCell generates revenue through the sale of its single-use CTC isolation kits. The company offers 7 different kit variants (CYTO, CSB, FCD, FCD-SP, LCD, MB, MBSB) designed for different downstream applications including cytology, molecular biology, and cell culture. Kits are sold directly to researchers, clinicians, and laboratories without requiring distribution intermediaries.

screencell.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1Custom quote-based pricing for CTC isolation kits
ModelUnit PricingBilling cadencePay-as-you-go
Notes

No standard pricing is publicly available. The company uses a quote request system where customers describe their project needs, select the kit type, and specify use case requirements (CTC enumeration, detection of CTC clusters, identification of therapeutic targets, evaluation of mutations, CTC culture, or other).

screencell.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1CYTO kit
Description

CTC isolation kit for cytology applications with fixed CTCs on isolation support, blood draw processed in under 4 hours.

screencell.com
+6 more records
Core offering1 text field

ScreenCell develops and manufactures single-use circulating tumor cell (CTC) isolation kits based on a patented, marker-independent microfiltration technology. The company sells 7 kit variants (CYTO, CSB, FCD, FCD-SP, MB, MBSB, LCD) designed for cytology, molecular biology, and cell culture downstream applications. Its products serve cancer researchers, clinical laboratories, and pharmaceutical companies globally.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • CTC enrichment in under 10 minutes
+3 more records
Product overview1 text field

ScreenCell offers a suite of 7 single-use CTC isolation kits (CYTO, CSB, FCD, FCD-SP, MB, MBSB, LCD) all powered by a patented morphology-based microfiltration technology. The kits are organized into three application domains: Cytology (CYTO, CSB), Molecular Biology (FCD, FCD-SP, MB, MBSB, LCD), and Cell Culture (MB, MBSB). The CYTO and CSB kits fix CTCs on the isolation support for cytomorphological analysis; the MB and MBSB kits recover viable CTCs for 2D/3D cell culture and molecular analyses; and the FCD, FCD-SP, and LCD kits provide flexible recovery options in suspension or on slides for downstream molecular biology. The company also manufactures the filtration hardware (the ScreenCell device) that underpins all kits, which requires no dedicated instrumentation. In January 2026, ScreenCell is standardizing its entire kit range to 2 filtration units per kit with 1 dilution buffer.

Product and service8 records
1ScreenCell CYTO Kit
CategoryCTC isolation consumables — cytology
Description

CTC isolation kit for rapid processing of blood samples collected less than 4 hours prior. Fixed CTCs are recovered on the isolation support, enabling cytomorphological analysis, CTC enumeration, and downstream cytological applications including MGG staining, immunofluorescence, and immunocytochemistry. Designed for cancer researchers and clinical laboratories.

2ScreenCell CSB Kit
CategoryCTC isolation consumables — cytology
Description

CTC isolation kit optimized for blood samples processed between 4 hours and 3 days after collection, providing flexibility for samples with delayed handling. CTCs are recovered on the isolation support for downstream cytological analyses. Designed for cancer researchers and clinical laboratories handling batched or transported samples.

3ScreenCell FCD Kit
CategoryCTC isolation consumables — molecular biology
Description

CTC isolation kit that enables recovery of CTCs either in suspension or on a microscope slide, offering flexibility for different downstream molecular biology applications. Targets cancer researchers requiring adaptable sample output formats.

4ScreenCell FCD-SP Kit
CategoryCTC isolation consumables — molecular biology
Description

CTC isolation kit variant that transfers isolated cells onto a glass slide, enabling direct cytological examination and visualization of CTCs for downstream applications.

5ScreenCell MB Kit
CategoryCTC isolation consumables — cell culture / molecular biology
Description

CTC isolation kit designed for the recovery of viable (live) CTCs from whole blood, enabling 2D and 3D cell culture, DNA and RNA extraction, and downstream molecular biology analyses including mutation detection (e.g., EGFR, KRAS) via ddPCR. Targets cancer researchers and translational scientists.

6ScreenCell MBSB Kit
CategoryCTC isolation consumables — cell culture / molecular biology
Description

CTC isolation kit variant for recovery of viable CTCs with compatibility for molecular biology applications, supporting DNA and RNA extraction from enriched CTC samples for cell culture and downstream analysis.

7ScreenCell LCD Kit
CategoryCTC isolation consumables — molecular biology
Description

CTC isolation kit designed for liquid biopsy applications where CTCs are recovered in suspension, enabling downstream molecular biology analyses. Targets cancer researchers performing liquid biopsy workflows.

8ScreenCell® Microfiltration Technology Platform
CategoryCTC isolation technology platform
Description

Patented morphology-based microfiltration technology platform for isolating circulating tumor cells (CTCs) and CTC clusters from whole blood of patients with solid tumors without immunological labeling. Validated across 16 cancer types including breast, lung, prostate, and colon cancers. Underpins the 7 ScreenCell CTC isolation kits.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
1Paris Saclay Cancer Cluster (PSCC)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-29
Description

ScreenCell participates in the Paris Saclay Cancer Cluster, a private non-profit French scientific cooperation foundation dedicated to oncology innovation. Founded by Gustave Roussy, Sanofi, Inserm, Paris-Saclay University, and Institut Polytechnique de Paris, PSCC brings together key partners including Unicancer, Institut Curie, AP-HP, and Medicen covering the entire oncology value chain.

screencell.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-01-29
Description

ScreenCell participates in the SU2C Scientific Summit 2026, a major oncology research event bringing together researchers and industry professionals to discuss the latest breakthroughs in cancer research.

3International Society for Liquid Biopsy (ISLB)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-01
Description

ScreenCell participates in ISLB's annual liquid biopsy conference, providing a platform to establish connections with North American and international thought leaders in liquid biopsy research and explore technological innovations.

4Advances in Circulating Tumor Cells (ACTC)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-09-24
Description

ScreenCell participates in the ACTC annual meeting focused on circulating tumor cell research.

screencell.com
5ISMRC (International Society for Mesenchymal Research on Cancer)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-05-07
Description

ScreenCell participates in ISMRC conferences to engage with the cancer research community.

screencell.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-21
Description

ScreenCell joined PMT Santé (formerly Innov'Health cluster) based in Besançon, France. PMT Santé brings together industrial companies, research laboratories, and academic stakeholders in the health sector in the Bourgogne-Franche-Comté region. The cluster supports the French medical device industry and promotes regional excellence in health, focusing on medtech and biotech ecosystems including bioproduction.

7European Liquid Biopsy Society (ELBS)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-10
Description

ScreenCell became an industry member of ELBS, a scientific society founded in 2019 and chaired by Prof. Dr. med. Klaus Pantel from University Medical Center Hamburg-Eppendorf (UKE). ELBS brings together over 100 European partners from academia, clinical practice, and industry with the mission of advancing liquid biopsy research and accelerating its deployment in clinical practice.

screencell.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2014-09-29
Description

ScreenCell entered a collaborative study with the Jefferson Breast Care Center at the Sidney Kimmel Cancer Center in Philadelphia to evaluate the effectiveness of ScreenCell's proprietary devices and protocols for enrichment of CTCs from peripheral blood in breast cancer patients. This collaboration addresses the limitation of EpCAM-dependent methods that miss 30-40% of metastatic breast cancer cases.

9Rouen University Hospital, Rome University Hospital-La Sapienza, University of Medicine and Pharmacy Cluj-Napoca
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2014-08-08
Description

Researchers at these institutions published a study in Cancer Biomarkers using the ScreenCell Cyto device to capture and characterize CTCs from colorectal cancer patients, demonstrating the technology's efficiency compared to immunomagnetic and microfluidic separation methods.

screencell.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Menarini Silicon Biosystems markets the FDA-cleared CELLSEARCH system, the clinical gold standard for CTC enumeration in metastatic breast, prostate, and colorectal cancer. Directly comparable to ScreenCell as both sell CTC isolation platforms to research and clinical oncology labs, though CellSearch is instrumented and ScreenCell is not.

TypeDirect peer
Description

ANGLE's Parsortix system is a microfluidic, label-free CTC isolation platform used in research and clinical studies across multiple cancer types. Directly comparable in technology philosophy (microfluidic / size-based capture without antibodies) and customer base (translational oncology labs), competing for the same research-use budget.

TypeDirect peer
Description

RareCyte offers an instrumented platform for CTC enumeration and single-cell retrieval from whole blood, used in academic and pharma research. Comparable to ScreenCell as a CTC-focused vendor serving translational oncology customers, though RareCyte's workflow relies on instrumentation and imaging rather than filtration alone.

TypeBroad incumbent
Description

Miltenyi Biotec is a major life-science tools vendor offering MACS-based cell separation, including positive/negative selection kits for CTC enrichment. Comparable as a broader incumbent in the cell-isolation space with overlapping research-customer base, though its core technology is antibody/magnetic-bead based rather than filtration.

TypeBroad incumbent
Description

STEMCELL Technologies supplies a broad portfolio of cell-separation and sample-preparation consumables for immunology, stem cell, and oncology research. Comparable as a life-science tools incumbent whose cell-isolation products compete for the same research budget as ScreenCell's CTC kits.

TypeBroad incumbent
Description

QIAGEN provides liquid-biopsy sample-preparation technologies (e.g., circulating nucleic-acid kits and CTC adjuncts) used by translational oncology labs. Comparable as a broad life-science tools incumbent whose products overlap the upstream sample-prep step of the same liquid-biopsy workflows ScreenCell serves.

TypeBroad incumbent
Description

Bio-Techne (R&D Systems, ProteinSimple, ExoDx) sells proteomic and liquid-biopsy reagents to research and clinical labs. Comparable as a broad life-science tools vendor whose products and customer base (cancer researchers, clinical labs) overlap with ScreenCell's, though Bio-Techne is not CTC-specific.

TypeEmerging player
Description

Biocept offers liquid-biopsy services and proprietary CTC and ctDNA assays targeting oncology treatment selection and monitoring. Comparable as a CTC-focused emerging player, though Biocept's model is service-based (CLIA lab) rather than kit-based like ScreenCell.

TypeEmerging player
Description

Apostle develops liquid-biopsy technologies including CTC and ctDNA isolation reagents using magnetic nanoparticle and biochemical approaches. Comparable as an emerging CTC / liquid-biopsy reagent vendor targeting research and translational customers similar to ScreenCell.

TypeEmerging player
Description

Canopy Biosciences (part of Bruker) provides single-cell and spatial multi-omics platforms used in translational oncology research. Comparable as an emerging player whose single-cell technologies are an alternative analytical pathway for CTCs and tumor-cell characterization in the same research labs ScreenCell serves.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ScreenCell

Liquid Biopsy / CTC Isolation Consumablesscreencell.com

ScreenCell is a French biotechnology company that commercializes a patented size-based microfiltration technology for isolating circulating tumor cells from whole blood, selling single-use consumable kits directly to academic, clinical, and pharmaceutical research customers across 30+ countries.

What ScreenCell does

ScreenCell is a French biotechnology company founded in 2010 and headquartered in Besançon, France, that develops and commercializes a patented microfiltration technology for isolating circulating tumor cells (CTCs) from whole blood. The company's core technology isolates CTCs based on cell size differential using a membrane filtration approach, eliminating the need for immunological labeling, dedicated instrumentation, or biomarker-based capture. This marker-independent method is positioned to capture a broader spectrum of CTCs, including subpopulations that have undergone epithelial-mesenchymal transition (EMT) and exhibit reduced EpCAM expression, which antibody-based methods miss.

ScreenCell commercializes its technology through a portfolio of seven single-use CTC isolation kits (CYTO, CSB, FCD, FCD-SP, MB, MBSB, LCD) addressing cytology, molecular biology, and cell culture applications. The company sells these consumables directly to academic researchers, clinical laboratories, pharmaceutical and biotech companies, and healthcare providers through a website-based quote system and direct email contact, with no distribution intermediaries. As of January 2026, ScreenCell standardized its kit range to a 2 filtration unit / 1 dilution buffer format with eco-friendly packaging, operationalizing a '1 kit = 1 patient' workflow. The technology is validated across 16 cancer types, supported by 70+ peer-reviewed publications, and has been used in over 30 countries by customers including Mayo Clinic, MSKCC, AP-HP, INSERM, Institut Gustave Roussy, and the University of Manitoba. ScreenCell maintains an 11-50 employee operation and is governed by a leadership team including CEO Nicolas Schlumberger, CSO Georges Uzan, and CTO Sina Naserian.

ScreenCell firmographics

Firmographics
Name
ScreenCell
Legal name
ScreenCell
Website
https://screencell.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
ScreenCell is a French biotechnology company that commercializes a patented size-based microfiltration technology for isolating circulating tumor cells from whole blood, selling single-use consumable kits directly to academic, clinical, and pharmaceutical research customers across 30+ countries.
Ownership category
akta.pro rank

ScreenCell industry classification

Industry
Product category
Liquid Biopsy / CTC Isolation Consumables
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAABAH
Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAANAC
Companion Diagnostics (CDx) Development & Commercialization

Keywords

  • Circulating tumor cells
  • CTC isolation kits
  • Liquid biopsy
  • Microfiltration technology
  • Cell isolation devices

Where ScreenCell is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices1 record

Markets served

ScreenCell business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. CTC Isolation Kits: ScreenCell generates revenue through the sale of its single-use CTC isolation kits. The company offers 7 different kit variants (CYTO, CSB, FCD, FCD-SP, LCD, MB, MBSB) designed for different downstream applications including cytology, molecular biology, and cell culture. Kits are sold directly to researchers, clinicians, and laboratories without requiring distribution intermediaries.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goCustom quote-based pricing for CTC isolation kits

Go-to-market motion2 records

Distribution channels2 records

Marketing channels8 records

ScreenCell product offering

Product offering

Core offering

ScreenCell develops and manufactures single-use circulating tumor cell (CTC) isolation kits based on a patented, marker-independent microfiltration technology. The company sells 7 kit variants (CYTO, CSB, FCD, FCD-SP, MB, MBSB, LCD) designed for cytology, molecular biology, and cell culture downstream applications. Its products serve cancer researchers, clinical laboratories, and pharmaceutical companies globally.

Product overview

ScreenCell offers a suite of 7 single-use CTC isolation kits (CYTO, CSB, FCD, FCD-SP, MB, MBSB, LCD) all powered by a patented morphology-based microfiltration technology. The kits are organized into three application domains: Cytology (CYTO, CSB), Molecular Biology (FCD, FCD-SP, MB, MBSB, LCD), and Cell Culture (MB, MBSB). The CYTO and CSB kits fix CTCs on the isolation support for cytomorphological analysis; the MB and MBSB kits recover viable CTCs for 2D/3D cell culture and molecular analyses; and the FCD, FCD-SP, and LCD kits provide flexible recovery options in suspension or on slides for downstream molecular biology. The company also manufactures the filtration hardware (the ScreenCell device) that underpins all kits, which requires no dedicated instrumentation. In January 2026, ScreenCell is standardizing its entire kit range to 2 filtration units per kit with 1 dilution buffer.

Differentiator

Problem solved

Functional benefit

Brands

  • CYTO kit: CTC isolation kit for cytology applications with fixed CTCs on isolation support, blood draw processed in under 4 hours.
  • CSB kit
  • FCD kit
  • FCD-SP kit
  • MB kit
  • MBSB kit
  • LCD kit

Products and services

  • ScreenCell CYTO Kit CTC isolation kit for rapid processing of blood samples collected less than 4 hours prior. Fixed CTCs are recovered on the isolation support, enabling cytomorphological analysis, CTC enumeration, and downstream cytological applications including MGG staining, immunofluorescence, and immunocytochemistry. Designed for cancer researchers and clinical laboratories.
  • ScreenCell CSB Kit CTC isolation kit optimized for blood samples processed between 4 hours and 3 days after collection, providing flexibility for samples with delayed handling. CTCs are recovered on the isolation support for downstream cytological analyses. Designed for cancer researchers and clinical laboratories handling batched or transported samples.
  • ScreenCell FCD Kit CTC isolation kit that enables recovery of CTCs either in suspension or on a microscope slide, offering flexibility for different downstream molecular biology applications. Targets cancer researchers requiring adaptable sample output formats.
  • ScreenCell FCD-SP Kit CTC isolation kit variant that transfers isolated cells onto a glass slide, enabling direct cytological examination and visualization of CTCs for downstream applications.
  • ScreenCell MB Kit CTC isolation kit designed for the recovery of viable (live) CTCs from whole blood, enabling 2D and 3D cell culture, DNA and RNA extraction, and downstream molecular biology analyses including mutation detection (e.g., EGFR, KRAS) via ddPCR. Targets cancer researchers and translational scientists.
  • ScreenCell MBSB Kit CTC isolation kit variant for recovery of viable CTCs with compatibility for molecular biology applications, supporting DNA and RNA extraction from enriched CTC samples for cell culture and downstream analysis.
  • ScreenCell LCD Kit CTC isolation kit designed for liquid biopsy applications where CTCs are recovered in suspension, enabling downstream molecular biology analyses. Targets cancer researchers performing liquid biopsy workflows.
  • ScreenCell® Microfiltration Technology Platform Patented morphology-based microfiltration technology platform for isolating circulating tumor cells (CTCs) and CTC clusters from whole blood of patients with solid tumors without immunological labeling. Validated across 16 cancer types including breast, lung, prostate, and colon cancers. Underpins the 7 ScreenCell CTC isolation kits.

Quantifiable outcome

  • CTC enrichment in under 10 minutes
  • +3 more outcomes

Companies that use ScreenCell

Customer profile

Named customers10 records

Segments3 records

Ideal customer profiles3 records

ScreenCell technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

ScreenCell partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • Paris Saclay Cancer Cluster (PSCC)coreStrategic or Co-development Partner · 29 January 2026ScreenCell participates in the Paris Saclay Cancer Cluster, a private non-profit French scientific cooperation foundation dedicated to oncology innovation. Founded by Gustave Roussy, Sanofi, Inserm, Paris-Saclay University, and Institut Polytechnique de Paris, PSCC brings together key partners including Unicancer, Institut Curie, AP-HP, and Medicen covering the entire oncology value chain.
  • Stand Up To Cancer (SU2C)minorStrategic or Co-development Partner · 29 January 2026ScreenCell participates in the SU2C Scientific Summit 2026, a major oncology research event bringing together researchers and industry professionals to discuss the latest breakthroughs in cancer research.
  • International Society for Liquid Biopsy (ISLB)coreStrategic or Co-development Partner · 1 November 2025ScreenCell participates in ISLB's annual liquid biopsy conference, providing a platform to establish connections with North American and international thought leaders in liquid biopsy research and explore technological innovations.
  • Advances in Circulating Tumor Cells (ACTC)minorStrategic or Co-development Partner · 24 September 2025ScreenCell participates in the ACTC annual meeting focused on circulating tumor cell research.
  • ISMRC (International Society for Mesenchymal Research on Cancer)minorStrategic or Co-development Partner · 7 May 2025ScreenCell participates in ISMRC conferences to engage with the cancer research community.
  • PMT SantécoreStrategic or Co-development Partner · 21 February 2025ScreenCell joined PMT Santé (formerly Innov'Health cluster) based in Besançon, France. PMT Santé brings together industrial companies, research laboratories, and academic stakeholders in the health sector in the Bourgogne-Franche-Comté region. The cluster supports the French medical device industry and promotes regional excellence in health, focusing on medtech and biotech ecosystems including bioproduction.
  • European Liquid Biopsy Society (ELBS)coreStrategic or Co-development Partner · 10 July 2024ScreenCell became an industry member of ELBS, a scientific society founded in 2019 and chaired by Prof. Dr. med. Klaus Pantel from University Medical Center Hamburg-Eppendorf (UKE). ELBS brings together over 100 European partners from academia, clinical practice, and industry with the mission of advancing liquid biopsy research and accelerating its deployment in clinical practice.
  • Sidney Kimmel Cancer Center at Thomas Jefferson UniversitycoreStrategic or Co-development Partner · 29 September 2014ScreenCell entered a collaborative study with the Jefferson Breast Care Center at the Sidney Kimmel Cancer Center in Philadelphia to evaluate the effectiveness of ScreenCell's proprietary devices and protocols for enrichment of CTCs from peripheral blood in breast cancer patients. This collaboration addresses the limitation of EpCAM-dependent methods that miss 30-40% of metastatic breast cancer cases.
  • Rouen University Hospital, Rome University Hospital-La Sapienza, University of Medicine and Pharmacy Cluj-NapocacoreStrategic or Co-development Partner · 8 August 2014Researchers at these institutions published a study in Cancer Biomarkers using the ScreenCell Cyto device to capture and characterize CTCs from colorectal cancer patients, demonstrating the technology's efficiency compared to immunomagnetic and microfluidic separation methods.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

ScreenCell competitors and assessment

Company assessment

Direct peers

  • Menarini Silicon Biosystems: Menarini Silicon Biosystems markets the FDA-cleared CELLSEARCH system, the clinical gold standard for CTC enumeration in metastatic breast, prostate, and colorectal cancer. Directly comparable to ScreenCell as both sell CTC isolation platforms to research and clinical oncology labs, though CellSearch is instrumented and ScreenCell is not.
  • ANGLE plc: ANGLE's Parsortix system is a microfluidic, label-free CTC isolation platform used in research and clinical studies across multiple cancer types. Directly comparable in technology philosophy (microfluidic / size-based capture without antibodies) and customer base (translational oncology labs), competing for the same research-use budget.
  • RareCyte: RareCyte offers an instrumented platform for CTC enumeration and single-cell retrieval from whole blood, used in academic and pharma research. Comparable to ScreenCell as a CTC-focused vendor serving translational oncology customers, though RareCyte's workflow relies on instrumentation and imaging rather than filtration alone.

Broad incumbents

  • Miltenyi Biotec: Miltenyi Biotec is a major life-science tools vendor offering MACS-based cell separation, including positive/negative selection kits for CTC enrichment. Comparable as a broader incumbent in the cell-isolation space with overlapping research-customer base, though its core technology is antibody/magnetic-bead based rather than filtration.
  • STEMCELL Technologies: STEMCELL Technologies supplies a broad portfolio of cell-separation and sample-preparation consumables for immunology, stem cell, and oncology research. Comparable as a life-science tools incumbent whose cell-isolation products compete for the same research budget as ScreenCell's CTC kits.
  • QIAGEN: QIAGEN provides liquid-biopsy sample-preparation technologies (e.g., circulating nucleic-acid kits and CTC adjuncts) used by translational oncology labs. Comparable as a broad life-science tools incumbent whose products overlap the upstream sample-prep step of the same liquid-biopsy workflows ScreenCell serves.
  • Bio-Techne: Bio-Techne (R&D Systems, ProteinSimple, ExoDx) sells proteomic and liquid-biopsy reagents to research and clinical labs. Comparable as a broad life-science tools vendor whose products and customer base (cancer researchers, clinical labs) overlap with ScreenCell's, though Bio-Techne is not CTC-specific.

Emerging players

  • Biocept: Biocept offers liquid-biopsy services and proprietary CTC and ctDNA assays targeting oncology treatment selection and monitoring. Comparable as a CTC-focused emerging player, though Biocept's model is service-based (CLIA lab) rather than kit-based like ScreenCell.
  • Apostle Sciences: Apostle develops liquid-biopsy technologies including CTC and ctDNA isolation reagents using magnetic nanoparticle and biochemical approaches. Comparable as an emerging CTC / liquid-biopsy reagent vendor targeting research and translational customers similar to ScreenCell.
  • Canopy Biosciences (Bruker): Canopy Biosciences (part of Bruker) provides single-cell and spatial multi-omics platforms used in translational oncology research. Comparable as an emerging player whose single-cell technologies are an alternative analytical pathway for CTCs and tumor-cell characterization in the same research labs ScreenCell serves.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

ScreenCell social profiles

Digital presence

ScreenCell financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ScreenCell leadership team

Management profile

Number of profiles

Profiles4 records

ScreenCell funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ScreenCell M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ScreenCell

What does ScreenCell do?

ScreenCell develops and manufactures single-use circulating tumor cell (CTC) isolation kits based on a patented, marker-independent microfiltration technology. The company sells 7 kit variants (CYTO, CSB, FCD, FCD-SP, MB, MBSB, LCD) designed for cytology, molecular biology, and cell culture downstream applications. Its products serve cancer researchers, clinical laboratories, and pharmaceutical companies globally.

Is ScreenCell a public or private company?

ScreenCell is a private company. It is classified as venture growth investor backed and is currently operating.

When was ScreenCell founded?

ScreenCell was founded in 2010. It employs 11 to 50 people.

Where is ScreenCell based?

ScreenCell is headquartered in Paris, France, in the Europe region.

How does ScreenCell make money?

One revenue line is on record: CTC Isolation Kits.

Who are ScreenCell's main competitors?

Direct peers on record are Menarini Silicon Biosystems, ANGLE plc and RareCyte. Broad incumbents are Miltenyi Biotec, STEMCELL Technologies, QIAGEN and Bio-Techne. Emerging players are Biocept, Apostle Sciences and Canopy Biosciences (Bruker).

Does ScreenCell have an API?

No public API is recorded for ScreenCell.

What industry is ScreenCell in?

ScreenCell's product category is Liquid Biopsy / CTC Isolation Consumables. Its primary akta.pro industry code is HLAAABAH, Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables), with a secondary code of HLAAANAC, Companion Diagnostics (CDx) Development & Commercialization. Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals